Elevra (ELVR) launches fully funded NAL expansion and issues options
Rhea-AI Filing Summary
Elevra Limited has filed a Form 6-K highlighting two developments. The company has broken ground on the fully funded expansion of its North American Lithium (NAL) operation, following a May 2026 A$275 million institutional placement that funded the project and strengthened its balance sheet.
Stage 1 of the NAL Expansion is targeted for completion in mid-CY27 and is expected to lift annual spodumene concentrate production capacity by 15–20% while reducing unit operating costs through scale and efficiency improvements. The filing also reports the issue of 5,276,387 unquoted ELVAN options, exercisable at $4.80 and expiring on 31-Dec-2028, contributing to a total of 8,000,000 ELVAN options on issue alongside 194,016,029 ordinary shares.
Positive
- Fully funded NAL expansion targeting 15–20% capacity uplift by mid-CY27, with expectations of lower unit operating costs through improved scale and efficiency.
Negative
- None.
Insights
Fully funded NAL expansion adds 15–20% capacity with new options issued.
The expansion of North American Lithium is notable because it is described as fully funded via an earlier A$275 million placement. Stage 1 aims for a 15–20% increase in spodumene concentrate capacity and lower unit operating costs by mid-CY27.
The filing also records issuance of 5,276,387 unquoted ELVAN options at $4.80, expiring 31-Dec-2028, taking total ELVAN options to 8,000,000 and ordinary shares to 194,016,029. Actual impact will depend on execution of the expansion and future lithium market conditions.

